Abstract
Patients with interstitial lung disease (ILD) suffer from poor quality of life and increased mortality. The poor quality of life is multifactorial, attributable in large part to respiratory symptoms and limitations, medication side effects, and the psychiatric effects of chronic illness. Sleep is affected by these same stresses, resulting in poor sleep quality and sleep disordered breathing. Sleep fragmentation, arousals, and Stage N1 sleep are all increased in patients with ILD. Sleep disordered breathing, in the form of nocturnal hypoxia and obstructive sleep apnea, is common in these patients as well. These sleep disorders are associated with indices of poor quality of life and excessive daytime sleepiness, and may be targets of therapy for the overall management of patients with ILD.
Keywords: Interstitial lung disease, restrictive lung disease, idiopathic pulmonary fibrosis, sleep, sleep disordered breathing
Current Respiratory Medicine Reviews
Title: Sleep in Interstitial Lung Disease
Volume: 5 Issue: 4
Author(s): Vidya Krishnan
Affiliation:
Keywords: Interstitial lung disease, restrictive lung disease, idiopathic pulmonary fibrosis, sleep, sleep disordered breathing
Abstract: Patients with interstitial lung disease (ILD) suffer from poor quality of life and increased mortality. The poor quality of life is multifactorial, attributable in large part to respiratory symptoms and limitations, medication side effects, and the psychiatric effects of chronic illness. Sleep is affected by these same stresses, resulting in poor sleep quality and sleep disordered breathing. Sleep fragmentation, arousals, and Stage N1 sleep are all increased in patients with ILD. Sleep disordered breathing, in the form of nocturnal hypoxia and obstructive sleep apnea, is common in these patients as well. These sleep disorders are associated with indices of poor quality of life and excessive daytime sleepiness, and may be targets of therapy for the overall management of patients with ILD.
Export Options
About this article
Cite this article as:
Krishnan Vidya, Sleep in Interstitial Lung Disease, Current Respiratory Medicine Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339809790112410
DOI https://dx.doi.org/10.2174/157339809790112410 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Comprehensive Review on Preclinical Evidence-based Neuroprotective
Potential of <i>Bacopa monnieri</i> against Parkinson's Disease
Current Drug Targets Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets Genetic Anomalies of the Respiratory Tract
Current Respiratory Medicine Reviews Immune Defence Mechanisms: Comparing Upper and Lower Airways in Chronic Airway Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy A Review of the Current Clinical Use of Quetiapine and Extended Release Quetiapine in the Management of Anxiety and Related Disorders
Current Psychopharmacology Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
CNS & Neurological Disorders - Drug Targets The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery <i>In-silico</i> Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Atypical antipsychotics and inverse agonism at 5-HT<sub>2</sub> receptors
Current Pharmaceutical Design Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia
Current Medicinal Chemistry Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders
Current Pharmaceutical Design Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets